<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589303</url>
  </required_header>
  <id_info>
    <org_study_id>06-004554</org_study_id>
    <nct_id>NCT00589303</nct_id>
  </id_info>
  <brief_title>AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study</brief_title>
  <acronym>PACIFIC</acronym>
  <official_title>Pacing and AV Node Ablation Compared to Drug Therapy in Symptomatic Elderly Patients With Atrial Fibrillation Clinical Trial (PACIFIC) - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether early atrioventricular node (AVN) ablation
      with pacing device therapy will reduce death and hospitalization when compared to the
      conventional drug therapy in elderly patients with recurrent and symptomatic atrial
      fibrillation (AF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiologic studies have shown that 70-80% of patients with atrial fibrillation are older
      than 65 years of age. Drug therapy for atrial fibrillation is not effective or not tolerated
      in many elderly patients, for both rate or rhythm strategies. Preliminary data from AVN
      ablation and pacemaker therapy demonstrated this strategy is highly effective in controlling
      symptoms among patients who have failed numerous drug therapy. Quality of life is improved
      while hospital admission and office visits are reduced.

      Pilot Study Design

        -  All patients will be 1:1 randomized to standard-care drug therapy (American College of
           Cardiology/American Heart Association Guideline, 2006) or AV node ablation and pacemaker
           therapy

        -  For patients randomized to AVN ablation, there will be a 1:1 sub-randomization to
           conventional right ventricular apex pacing or cardiac resynchronization therapy
           (biventricular pacing)

        -  All patients will be followed at 2 and 6 months from the time of randomization in the
           pilot study.

        -  A total of 60 patients from 5-15 clinical sites will be enrolled during an active
           recruiting period of 12 months for the pilot study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Hospitalization Within Six Months of Enrollment</measure>
    <time_frame>Six months after enrollment</time_frame>
    <description>Number of patients who were hospitalized for cardiovascular problems within 6 months of enrollment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Drug Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved rate and rhythm control drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrioventricular Node (AVN) Ablation / Pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AV Node ablation and device implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDA approved rate and rhythm control drugs</intervention_name>
    <description>Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.
Rate Control:
Beta-Blocker:
metoprolol
atenolol
carvedilol
Calcium Channel Blocker:
verapamil
diltiazem
Rhythm Control:
procainamide
quinidine
disopyramide
propafenone
flecainide
sotalol
dofetilide
amiodarone</description>
    <arm_group_label>Drug Therapy</arm_group_label>
    <other_name>Lopressor</other_name>
    <other_name>Toprol XL</other_name>
    <other_name>Tenormin</other_name>
    <other_name>Coreg</other_name>
    <other_name>Isoptin</other_name>
    <other_name>Verelan</other_name>
    <other_name>Verelan PM</other_name>
    <other_name>Calan</other_name>
    <other_name>Bosoptin</other_name>
    <other_name>Covera-HS</other_name>
    <other_name>Cardizem</other_name>
    <other_name>Pronestyl</other_name>
    <other_name>Norpace</other_name>
    <other_name>Rythmol</other_name>
    <other_name>Betapace</other_name>
    <other_name>Tikosyn</other_name>
    <other_name>Cordarone</other_name>
    <other_name>Pacerone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AV Node ablation and device implant</intervention_name>
    <description>Pacing Systems:
Enpusle Premarket Approval Number (PMA#) P980035
EnRhythm PMA# P980035
Adapta PMA# P980035
Cardiac Resynchronization Therapy (CRT) Pacing Systems:
- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031
Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:
EnTrust PMA# P980016
Virtuoso PMA# P980016
ICD CRT Pacing Systems:
InSync Maximo PMA# P980016
InSync Sentry PMA# P890003
Concerto PMA# P980016</description>
    <arm_group_label>Atrioventricular Node (AVN) Ablation / Pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 65 years

          -  Paroxysmal, persistent, or permanent atrial fibrillation

          -  Index event of atrial fibrillation is documented on electrocardiogram or rhythm strip.
             Atrial fibrillation must be the qualifying event. Atrial flutter can have been present
             in the past, but it must not be considered the index arrhythmia.

          -  Paroxysmal atrial fibrillation episodes must be recurrent (two or more episodes in the
             past 6 months). At least one of the paroxysmal episodes must be &quot;sustained&quot;, defined
             as lasting greater than 1 hour documented by a Holter monitor or by history in
             conjunction with an ECG or a rhythm strip.

          -  At least one attempt of unsuccessful drug therapy, either for rate, for rhythm, or for
             rate-and-rhythm control.

          -  Symptoms related to atrial fibrillation within the last 6 months

          -  Eligible for long-term treatment with both treatment strategies

          -  Must provide informed consent, Health Insurance Portability and Accountability Act
             (HIPAA) authorization, and be willing to comply with follow-up requirements.

        Exclusion Criteria:

          -  Reversible causes of atrial fibrillation

          -  On heart transplant list

          -  Familial cardiac conditions with increased risk of sudden death

          -  Asymptomatic

          -  Medical condition limiting expected survival to be less than one year

          -  Contraindications to anticoagulation

          -  Pre-existing implanted pacemaker, implantable automatic cardioverter-defibrillator or
             cardiac resynchronization device.

          -  Pre-existing indication for permanent pacemaker, implantable automatic
             cardioverter-defibrillator or cardiac resynchronization device

          -  More than one attempt of drug therapy for rate, for rhythm, or for rate-and-rhythm
             control

          -  Planned major surgery within the next six months, including thoracic surgery

          -  Disability that would preclude collection of study data or have co-morbidity that
             would contraindicate device implantation

          -  Participated in another clinical trial within the previous 30 days using a therapeutic
             modality which could have potential residual effects that might confound the results
             of this pilot study

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Win K Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Group</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Heart Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary and Calgary Health Region</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N-4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1834-40.</citation>
    <PMID>12466507</PMID>
  </reference>
  <reference>
    <citation>Bradley DJ, Shen WK. Atrioventricular junction ablation combined with either right ventricular pacing or cardiac resynchronization therapy for atrial fibrillation: the need for large-scale randomized trials. Heart Rhythm. 2007 Feb;4(2):224-32. Epub 2006 Oct 20.</citation>
    <PMID>17275763</PMID>
  </reference>
  <reference>
    <citation>Bradley DJ, Shen WK. Overview of management of atrial fibrillation in symptomatic elderly patients: pharmacologic therapy versus AV node ablation. Clin Pharmacol Ther. 2007 Feb;81(2):284-7. Review.</citation>
    <PMID>17259952</PMID>
  </reference>
  <reference>
    <citation>Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med. 2001 Apr 5;344(14):1043-51.</citation>
    <PMID>11287974</PMID>
  </reference>
  <reference>
    <citation>Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL, Gibbons RJ, Antman EM, Alpert JS, Gregoratos G, Hiratzka LF, Faxon DP, Jacobs AK, Fuster V, Smith SC Jr; American College of Cardiology/American Heart Association Task Force on Practice Guidelines/North American Society for Pacing and Electrophysiology Committee to Update the 1998 Pacemaker Guidelines. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 2002 Oct 15;106(16):2145-61.</citation>
    <PMID>12379588</PMID>
  </reference>
  <reference>
    <citation>Fuster V, Ryd√©n LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006 Aug 15;114(7):e257-354. Erratum in: Circulation. 2007 Aug 7;116(6):e138.</citation>
    <PMID>16908781</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <results_first_submitted>February 25, 2013</results_first_submitted>
  <results_first_submitted_qc>February 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2013</results_first_posted>
  <last_update_submitted>February 25, 2013</last_update_submitted>
  <last_update_submitted_qc>February 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <name_title>Win K Shen MD</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>AV Node ablation</keyword>
  <keyword>Cardiac pacemaker</keyword>
  <keyword>Antiarrhythmic drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 5 sites: (Mayo Clinic in Scottsdale, Arizona; Mayo Clinic in Rochester, Minnesota; Oregon Health and Science University in Portland, Oregon; University of Calgary in Calgary, Alberta, Canada; and The Heart Group in Evansville, Indiana.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Drug Therapy</title>
          <description>FDA approved rate and rhythm control drugs</description>
        </group>
        <group group_id="P2">
          <title>Atrioventricular Node (AVN) Ablation / Pacing</title>
          <description>Atrioventricular Node ablation and device implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug Therapy</title>
          <description>FDA approved rate and rhythm control drugs</description>
        </group>
        <group group_id="B2">
          <title>Atrioventricular Node (AVN) Ablation / Pacing</title>
          <description>Atrioventricular Node ablation and device implant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Hospitalization Within Six Months of Enrollment</title>
        <description>Number of patients who were hospitalized for cardiovascular problems within 6 months of enrollment.</description>
        <time_frame>Six months after enrollment</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Therapy</title>
            <description>FDA approved rate and rhythm control drugs</description>
          </group>
          <group group_id="O2">
            <title>Atrioventricular Node (AVN) Ablation / Pacing</title>
            <description>Atrioventricular Node ablation and device implant</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Hospitalization Within Six Months of Enrollment</title>
          <description>Number of patients who were hospitalized for cardiovascular problems within 6 months of enrollment.</description>
          <population>Intent-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All subjects had a follow up at 2 and 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Drug Therapy</title>
          <description>FDA approved rate and rhythm control drugs</description>
        </group>
        <group group_id="E2">
          <title>Atrioventricular Node (AVN) Ablation / Pacing</title>
          <description>Atrioventricular Node ablation and device implant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lead Reposition</sub_title>
                <description>The lead to the pacemaker had to be repositioned.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Volume Depletion</sub_title>
                <description>Volume depletion is the loss of both water and salts from cell volume.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid accumulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Left upper extremity swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Stimulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Chronic Obstructive Pulmonary Disease (COPD)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumothroax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated when about half of the subjects were enrolled due to lack of funding.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Win K. Shen</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>480-342-0348</phone>
      <email>wshen@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

